Pharma
-
Permission granted by Bristol Myers Squibb
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak
While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease
By PharmaVoice staff • June 5, 2026 -
Don Murray via Getty Images
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.
By Kelly Bilodeau • June 5, 2026 -
Explore the Trendlineâž”
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Getty Images
House bill aims to crack down on China biotech deals
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
By Kristin Jensen • June 4, 2026 -
Getty Images
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
By Kelly Bilodeau • June 4, 2026 -
Getty Images
When the ISS comes down, will its drug R&D be lost in space?
As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.
By Meagan Parrish • June 3, 2026 -
Getty Images
As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next
The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.
By Kelly Bilodeau • June 2, 2026 -
Christopher Furlong via Getty Images
AstraZeneca aims for a new blockbuster run in cardio disease
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.
By Alexandra Pecci • June 1, 2026 -
Getty Images
Can AI crack pharma’s drug repurposing goldmine?
With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.
By Alivia Kaylor • May 29, 2026 -
Getty Images
Longevity science picks up steam in pharma
Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.
By Kelly Bilodeau • May 29, 2026 -
Getty Images
Vertex’s Journavx made history, but left a void in the pain space
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
By Kelly Bilodeau • May 28, 2026 -
Permission granted by Bristol Myers Squibb
Q&AIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
By Jacob Bell • May 27, 2026 -
Getty Images
Can a chaotic FDA still deliver on faster drug development?
As leadership changes create more instability at the agency, here's what it'll take to keep speedier drug approvals on track.
By Kelly Bilodeau • May 26, 2026 -
Getty Images
Who’s winning pharma’s innovation race? The rankings are out.
While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.
By Meagan Parrish • May 22, 2026 -
Permission granted by American Biotech Innovation Alliance
Q&AChina’s biotech rise sparks new US industry alliance
The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.
By Kelly Bilodeau • May 21, 2026 -
Getty Images
Big Pharma is gambling on specialized R&D. Will it pay off?
Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.
By Kelly Bilodeau • May 20, 2026 -
Courtesy of Regeneron Pharmaceuticals
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
By Ben Fidler • May 19, 2026 -
Getty Images
Race intensifies to lead next wave of obesity drugs as trial results loom
As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.
By Kelly Bilodeau • May 18, 2026 -
Alex Wong via Getty Images
Sanofi’s vaccine bump; the new FDA commish
A look at how vaccine makers are scraping by, and at the incoming acting FDA head, Kyle Diamantas.
By PharmaVoice staff • May 15, 2026 -
Permission granted by Ovid Therapeutics
Q&AFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech
The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.
By Meagan Parrish • May 15, 2026 -
Getty Images
India’s pharma industry is going global. But can it catch up to China?
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
By Kelly Bilodeau • May 13, 2026 -
Getty Images
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.
By Alivia Kaylor • May 13, 2026 -
Permission granted by Sanofi
How tough is it getting for vaccine makers in the U.S.?
As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.
By Kelly Bilodeau • May 12, 2026 -
Permission granted by Curium
Sponsored by CuriumWhen reliability becomes patient care in nuclear medicine
Making reliability a clinical imperative can help scale theranostics beyond flagship centers.
By Renaud Dehareng, Group CEO, Curium • May 11, 2026 -
Getty Images
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
By Kelly Bilodeau • May 8, 2026 -
Permission granted by Novo Nordisk
Novo hikes guidance on Wegovy pill’s fast sales start
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report.
By Kristin Jensen • May 7, 2026
